BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 3, 2026
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Australia moves toward aligning device regulations with the European Union

Aug. 2, 2017
By Tamra Sami

Australian patients get help via amended access plan for unapproved drugs, devices

Aug. 2, 2017
By Tamra Sami
PERTH, Australia – Patients in Australia will now be able to get unapproved drugs through their doctors more quickly since Australia amended its drug and device regulations earlier this year.
Read More

Australian patients get help via amended access plan for unapproved drugs, devices

Aug. 1, 2017
By Tamra Sami

Australian patients get help via amended access plan for unapproved drugs, devices

July 31, 2017
By Tamra Sami
PERTH, Australia – Patients in Australia will now be able to get unapproved drugs through their doctors more quickly since Australia amended its drug and device regulations earlier this year.
Read More

Speedx aims to market first molecular test for antibiotic-resistant emerging STD

July 28, 2017
By Tamra Sami

Dimerix's lead compound meets primary endpoints in phase II CKD trial

July 19, 2017
By Tamra Sami
PERTH, Australia – Dimerix Ltd. reported positive phase IIa data with its lead program, DMX-200, in chronic kidney disease. The dose-escalation trial met the primary endpoints of safety and tolerability, and it met secondary efficacy endpoints with 25 percent of patients achieving a greater than 50 percent reduction in proteinuria, which is over and above the standard of care, CEO Kathy Harrison told investors during a conference call last Thursday.
Read More

Australia device trials grow with increase in government-backed infrastructure

July 17, 2017
By Tamra Sami

Dimerix's lead compound meets primary endpoints in phase II CKD trial

July 14, 2017
By Tamra Sami
PERTH, Australia – Dimerix Ltd. reported positive phase IIa data with its lead program, DMX-200, in chronic kidney disease.
Read More

Proposal to use Australian conformity assessment bodies gets mixed response

July 13, 2017
By Tamra Sami

Device manufacturers laud regulator move to handle all DTC ad complaints in Australia

July 12, 2017
By Tamra Sami
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 3, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing